European Launch of Acticoat(TM) Flex with NUCRYST's Nanocrystalline Silver Technology Announced by Smith Nephew
03 Setembro 2009 - 11:19AM
PR Newswire (US)
PRINCETON, NJ, Sept. 3 /PRNewswire-FirstCall/ -- NUCRYST
Pharmaceuticals, a developer and manufacturer of medical products
that fight infection and the Advanced Wound Management division of
Smith Nephew plc announced today the European launch of
Acticoat(TM) Flex3 and Acticoat(TM) Flex7. The Flex range is the
newest addition to the Acticoat(TM) portfolio of dressings with
NUCRYST's proprietary SILCRYST(TM) nanocrystalline silver coatings.
Acticoat(TM) Flex is an antimicrobial barrier dressing designed to
conform to body contours and allow for flexible movement for
injuries that require sustained antimicrobial activity. "We are
pleased to support Smith Nephew in the European launch of
Acticoat(TM) Flex," said David B. Holtz, Interim President and
Chief Executive Officer, and Chief Financial Officer of NUCRYST.
"The enhanced conformability of Flex will now be available to
European clinicians to simplifying the dressing of wounds on
difficult-to-protect articulating regions such as knee or elbow
joints while also providing advanced antimicrobial protection." The
CE Mark Certification for Acticoat(TM) Flex was received by Smith
Nephew last week following the July 510(k) clearance in the United
States and market approval in Canada late last year. "We are
delighted that we can now offer our European clinicians this new
version of Acticoat(TM). The feedback on Acticoat(TM) Flex from the
markets where it recently became available has been excellent,"
commented Roger Teasdale, President of Smith Nephew Wound
Management. "We are committed to improving the quality of life of
the patients treated with our products like Acticoat(TM) Flex,
which helps manage the risk of infection in patients with serious
wounds." About Acticoat(TM) Dressings with SILCRYST(TM)
Nanocrystals Acticoat(TM) dressings with NUCRYST's proprietary
SILCRYST(TM) nanocrystalline silver coatings provide effective
antimicrobial activity thereby providing an improved environment
for wound closure. Acticoat(TM) dressings are now sold by Smith
Nephew in over 30 countries and are used extensively for serious
wounds and traumatic injury. About Smith Nephew Smith Nephew is a
global medical technology business, specialising in Orthopaedics,
including Reconstruction, Trauma and Clinical Therapies, Endoscopy
and Advanced Wound Management products. Smith Nephew is a global
leader in arthroscopy and advanced wound management and is one of
the leading global orthopaedics companies. Smith Nephew is
dedicated to helping improve people's lives. The Company prides
itself on the strength of its relationships with its surgeons and
professional healthcare customers, with whom its name is synonymous
with high standards of performance, innovation and trust. The
Company operates in 32 countries around the world. Annual sales in
2008 were $3.8 billion. About NUCRYST Pharmaceuticals NUCRYST
Pharmaceuticals (NASDAQ: NCST; TSX: NCS) develops manufactures and
commercializes and using SILCRYST(TM), its patented atomically
disordered nanocrystalline silver technology. NUCRYST licensed
world-wide rights for SILCRYST(TM) wound care coating products to
Smith Nephew plc, which markets these products in over 30 countries
under their Acticoat(TM) trademark. NUCRYST is also developing
pharmaceutical products to address medical conditions that are
characterized by pain, infection and inflammation. The Company has
developed its proprietary nanocrystalline silver in a powder form,
referred to as NPI 32101, for use in medical devices and as an
active pharmaceutical ingredient. Acticoat(TM) is a trademark of
Smith Nephew plc SILCRYST(TM) is a trademark of NUCRYST
Pharmaceuticals Corp. This news release contains forward-looking
statements within the meaning of securities legislation in the
United States and Canada (collectively "forward-looking
statements"). The words "believes", "expects", "plans",
"anticipates", "estimates", "intends", "projects", "may", "might",
"would", "will", "could", "should" and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words.
Forward-looking statements in this news release include, but are
not limited to, statements about: the future plans of our
management in relation to resolving our exchange listing
deficiency. With respect to the forward-looking statements
contained in this news release, readers are cautioned that numerous
risks, uncertainties and other factors could cause our actual
results to differ materially from those indicated in these
statements including, but not limited to: the performance of stock
markets generally; our ability to satisfy regulatory and stock
exchange standards and requirements to maintain our exchange
listing; our future operation results are uncertain and likely to
fluctuate; our ability to maintain our collaboration with Smith
Nephew; our reliance on sales of Acticoat(TM) products with our
SILCRYST(TM) coatings by Smith Nephew; future financial performance
and operating performance of Smith Nephew; we may not be able to
retain existing and obtain new regulatory approvals for any future
products; continued development and market acceptance of new
products; the impact of delays and challenges with new product
introductions; the impact of new product introductions on the sales
of existing products; the impact of competitive products and
pricing; we may not be able to establish successful
commercialization programs, through new corporate collaborations or
otherwise; changes in currency exchange rates; our ability to
protect our intellectual property rights and to not infringe on the
intellectual property rights of others. Although we have attempted
to identify the important risks, uncertainties and other factors
that could cause actual results or events to differ materially from
those expressed or implied in forward-looking statements, there may
be other factors that cause actual results or events to differ from
those expressed or implied in forward looking statements. For a
more thorough discussion of the risks associated with our business,
see the "Risk Factors" section in our Annual Report on Form 10-K
for the year ended December 31, 2008 and in our Quarterly Report on
Form 10-Q for the quarter ended June 30, 2009, filed with the U.S.
Securities and Exchange Commission on EDGAR at http://www.sec.gov/
and with securities authorities in Canada on SEDAR at
http://www.sedar.com/. All forward-looking statements are expressly
qualified in their entirety by this cautionary statement and
NUCRYST disclaims any intention or obligation to revise or update
any forward-looking statements whether as a result of new
information, future developments or otherwise after the date
hereof. DATASOURCE: NUCRYST Pharmaceuticals Corp. CONTACT: David
Wills/Gillian McArdle, Investor Relations, (416) 504-8464,
Copyright